128 related articles for article (PubMed ID: 38395220)
1. Recurrent and persistent fever after SARS-CoV-2 infection in patients with follicular lymphoma: A case series.
Huang L; Tong X; Cui J; Du X; Liao Y; Tan X; Ju Y; Zhong X; Zhou W; Xu X; Li Y
Int J Infect Dis; 2024 Apr; 141():106973. PubMed ID: 38395220
[TBL] [Abstract][Full Text] [Related]
2. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
5. [Migratory pulmonary ground glass opacities caused by SARS-CoV-2 infection in a patient on B-cell depletion therapy].
Wang SY; Wang YM; Liu M; Zhao L; Cao B
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Dec; 46(12):1233-1239. PubMed ID: 38044051
[TBL] [Abstract][Full Text] [Related]
6. Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection.
Ito W; Fukumori T; Asaoka N; Imakita N; Nishimura T; Furukawa R; Nishihara Y; Fujikura H; Sekine T; Yamaguchi N; Hirata Y; Miyamoto S; Kanno T; Katano H; Suzuki T; Kasahara K
J Infect Chemother; 2024 Jul; 30(7):659-663. PubMed ID: 38184107
[TBL] [Abstract][Full Text] [Related]
7. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
[TBL] [Abstract][Full Text] [Related]
8. Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health system.
Malden DE; McLaughlin JM; Hong V; Lewnard J; Ackerson BK; Puzniak L; Kim JS; Takhar H; Frankland TB; Slezak JM; Tartof SY
Sci Rep; 2024 Mar; 14(1):7485. PubMed ID: 38553527
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
[TBL] [Abstract][Full Text] [Related]
10. In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes.
Chagla Z
Ann Intern Med; 2024 Jan; 177(1):JC7. PubMed ID: 38163374
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
Lindahl AL; Ahava MJ; Haukipää M; Kreivi HR; Lipponen A; Kortela E
Infect Dis (Lond); 2023 Aug; 55(8):585-589. PubMed ID: 37334428
[TBL] [Abstract][Full Text] [Related]
12. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
13. Delayed treatment with nirmatrelvir/ritonavir could remain effective in patients with Omicron BA2.2 variant of COVID-19.
Wang W; Wan J; Du W; Song J; Lu Y; Gu S; Feng Y; Wang G; Tao M; Yin J
Ann Acad Med Singap; 2023 Mar; 52(3):158-160. PubMed ID: 38904494
[No Abstract] [Full Text] [Related]
14. High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy.
Dong R; Huang Y; Ling X; Li L; Yu W; Jiang S
Int J Antimicrob Agents; 2024 Jan; 63(1):106997. PubMed ID: 37848106
[TBL] [Abstract][Full Text] [Related]
15. Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
Charness ME; Gupta K; Stack G; Strymish J; Adams E; Lindy DC; Mohri H; Ho DD
N Engl J Med; 2022 Sep; 387(11):1045-1047. PubMed ID: 36069968
[No Abstract] [Full Text] [Related]
16. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
[TBL] [Abstract][Full Text] [Related]
17. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
[TBL] [Abstract][Full Text] [Related]
18. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.
Maruki T; Nomoto H; Iwamoto N; Yamamoto K; Kurokawa M; Iwatsuki-Horimoto K; Yamayoshi S; Suzuki Y; Kawaoka Y; Ohmagari N
J Infect Chemother; 2024 Aug; 30(8):793-795. PubMed ID: 38242284
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
Parums DV
Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
[TBL] [Abstract][Full Text] [Related]
20. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
